Thank you for Subscribing to Life Science Review Weekly Brief
Bruker has announced the launch of two newtimsTOF tools. They are making major advances in unbiased single cell-proteomics, and phosphoproteomics, .
FREMONT CA: To address new quantitative questions in single-cell biology and pathobiology, Mann-group published a paper demonstrating unbiased, real single cell proteomics on over 1400 protein groups on a timsTOF R&D prototype. Frank H.Laukien, Bruker President and CEO has advanced the development of its timsTOF SCP system, which is now available for unbiased, quantitative single-cell 4D-Proteomics and ultra-sensitive neoantigen identification in immunopeptidomics.
Since its launch in 2017, the timsTOF Pro system has provided researchers with new capabilities in unbiased CCS-enabled 4D-Proteomics, typically on 5x-20x lower sample amounts and with 3x-5x faster run times for single shot, deep proteomics - with positive output and exceptional strength.
Bruker is on the forefront of the revolution in CCS-enabled 4D-Proteomics, and in 4D-Epiproteomics with the release of the next-generation timsTOF Pro 2. The timsTOF Pro 2 provides in-depth proteome coverage of >6000 protein groups and >60000 distinctive peptides in 60-minute gradients on 200ng HeLa digests. The exceptional timsTOF Pro 2 sensitivity notably upgrades methods to figure out post-translational modifications (PTMs), for instance, phosphoproteomics and ubiquitination studies, for CCS-enables, impartial, large-scale 4D-Epiproteomics, which is extremely significant in physiology, cell biology, and disease biology, particularly in cancer.
Bruker announced new 4D-Proteomics capabilities in their PaSER real-time search software. Using the unique tims/PASEF methodologies, the new PaSER 2022 provides large-scale CCS-enabled bioinformatics. The new TIMScoreTM, for example, uses the fourth dimension of large-scale collision cross sections (CCS) on all measured peptides to improve the confidence of peptide IDs. Increased confidence using CCS minimises the ambiguity of redundant peptide sequences, leading to more protein groups and unique peptide identifications with the same FDR threshold.
Bruker believes that the timsTOF SCP is a comprehensive new tool for unbiased, deep, and quantitative single-cell biology that corresponds to scRNA-seq. Basic research in single-cell biology and pathology will benefit substantially from merging transcriptomics with unbiased, deep, and quantitative proteomics and epi proteomics data for multiomic biomarker panels in the future. He continued saying that an unmet clinical need in liquid biopsies for increased cancer stage I/II detection sensitivity was necessary, including improved positive predictive values, as well as for early diagnosis of therapy resistance. Unbiased proteomics and PTMs are extremely complementary to NGS for attaining future important advances in PPV for the benefit of patients in both cancer cell genomics and epiproteomics, as well as in host immune response and tumor microenvironment.